Business Category: Biotechnology Healthcare
Startup Stage: Under Development
Support Required: Others
Structure of the Company: PVT Ltd.
Executive Summary: A serpentarium, venom bank and research center. For the first time in India, "region specific" snake venom with "batch numbers & traceability" would be harvested, processed, preserved and presented as per WHO laid quality guidelines. Monosha Biotech would be a platform of global standard facilitating research in the enigmatic and "not much" explored subject of ophiology and venom science, leading to the development of new life-saving drugs and simultaneously promoting an environment of human-snake harmonious coexistence needed for maintaining the ecological balance.
Market need: WHO has announced snakebite to be a "Neglected Tropical Disease", and India being the "snakebite death capital of the world", with more than 50000 deaths reported every year, out of 125000 deaths globally. Four to five times of this number are the people who are permanently disabled. As per a report of the Ministry of Health &Family Welfare, GoI, only 7.23% snakebite deaths are officially reported. Hence, the "Actual Number" of snakebite deaths every year in India is many times more than “just 50000". The poor, impoverished, rural people suffer the most from snakebites. Hence snakebite fuels the vicious cycle of poverty and is affecting the whole socio-economic edifice of our country. For the antivenom (ASV) to be effective, it should be made ONLY from the venom of snakes pertaining to the particular geographic region where the snakebite has occurred and the patient is being treated. Unfortunately, the ASVs manufactured in India for more than four decades now, are being manufactured from snake venom collected from the snakes of "just one/two districts of this vast country, and that too not as per the WHO laid quality guidelines and far less than the demand. Hence, even after administering far higher than the recommended dosage of this ASVs, the poor patients are not surviving. This is leading to LOSS OF LIVES and ECONOMIC LOSS for the Government (snakebite death compensation and subsidized ASVs). Researchers and scientists are always in search of “new leads” for developing life-saving drugs. Non-availability of these creates hindrance and delay. Venom holds new vistas for the development of life-saving drugs. Companies manufacturing and exporting ASVs from India are either using the Indian snake venom or are importing the venom as the “active ingredient”. In the first case, the ASVs produced is proving to be ineffective and the second case is leading to foreign exchange drainage and simultaneous increased cost of production. This is leading to an erosion of brand equity (both of the companies and of India being the country of origin) and profitability.
Product/Service description: " Region specific Lyophilised snake venom" with batch numbers and traceability, harvested, processed, preserved and supplied as per WHO laid quality guidelines.
Customers/Users: Antivenom manufacturers, research institutes, universities/colleges, pharmaceutical companies, cosmetic manufacturers.
Revenue Model: Selling lyophilised venom.